Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2

J Urol. 2016 Mar;195(3):608. doi: 10.1016/j.juro.2015.12.011. Epub 2015 Dec 10.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / economics*
  • Antineoplastic Agents / economics*
  • Carcinoma, Renal Cell / economics*
  • Female
  • Health Care Costs*
  • Humans
  • Immunologic Factors / economics*
  • Kidney Neoplasms / economics*
  • Male
  • Protein Kinase Inhibitors / economics*
  • Registries*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Immunologic Factors
  • Protein Kinase Inhibitors